Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
NCT06621654Phase 1Active, not recruiting
- Sponsor
- CanSino Biologics Inc.
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of haemophilus influenzae type b conjugate vaccine in Haemophilus influenzae type b infection (Hib) (7 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Adverse reactions at 30 days. Started Nov 2024; status: active, not recruiting.
02
Drugs
haemophilus influenzae type b conjugate vaccine
03
Conditions
Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT06621654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621654.